The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
The new facility will be able to handle four times as many patients as the previous facility.
Subscribe To Our Newsletter & Stay Updated
